BioCentury | Dec 1, 2016
Clinical News

ErepoXen: Additional Ph II data

...the third cohort of an open-label, South African and Australian Phase II trial showed that ErepoXen...
...the therapeutic range of 10-12 g/dL. When hemoglobin levels reached the therapeutic range, patients received ErepoXen...
...of the trial (see BioCentury, Aug. 3, 2015 ). SynBio has rights to co-develop Xenetic’s ErepoXen...
BioCentury | Aug 3, 2015
Clinical News

ErepoXen: Phase II data

...second cohort of an open-label, New Zealand and Australian Phase II trial showed that biweekly ErepoXen...
...the therapeutic range of 10-12 g/dL. When hemoglobin levels reached the therapeutic range, patients received ErepoXen...
...weeks and levels were maintained in the range for the remainder of the 17-week study. ErepoXen...
BioCentury | Apr 21, 2014
Company News

Xenetic hematology news

...area having a wealth of talent in orphan drug development and market launch expertise." Xenetic's ErepoXen...
BioCentury | Nov 18, 2013
Company News

General Sales and Leasing, Xenetic Biosciences deal

...the "first step" to listing on a U.S. stock exchange (see BioCentury, Oct. 28). Xenetic's ErepoXen...
BioCentury | Nov 4, 2013
Clinical News

ErepoXen: Phase II started

...began an open-label, New Zealand and Australian Phase II trial to evaluate multiple doses of ErepoXen...
...who are not receiving dialysis or erythropoiesis-stimulating agents (ESAs). SynBio has rights to co-develop Xenetic's ErepoXen...
...Xenetic Biosciences plc (LSE:XEN), London, U.K. Serum Institute of India Ltd. , Pune, India Product: ErepoXen...
BioCentury | Oct 28, 2013
Company News

General Sales & Leasing Inc. (GSL), Xenetic Biosciences deal

...GSL made a non-binding offer to acquire the share capital of Xenetic Biosciences. Xenetic's ErepoXen is...
BioCentury | Aug 12, 2013
Clinical News

ErepoXen: Phase II started

...begin an open-label, New Zealand and Australian Phase II trial to evaluate multiple doses of ErepoXen...
...who are not receiving dialysis or erythropoiesis-stimulating agents (ESAs). SynBio has rights to co-develop Xenetic's ErepoXen...
...Xenetic Biosciences plc (LSE:XEN), London, U.K. Serum Institute of India Ltd. , Pune, India Product: ErepoXen...
BioCentury | May 20, 2013
Clinical News

ErepoXen: Phase III started

...Xenetic said partner SynBio began a 24-month, open-label, Russian Phase III trial comparing ErepoXen vs. Aranesp...
...CKD. Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) markets Aranesp. SynBio has rights to co-develop Xenetic's ErepoXen...
...Biosciences plc (LSE:XEN; OTCBB:XENEF), London, U.K. Serum Institute of India Ltd. , Pune, India Product: ErepoXen...
BioCentury | Feb 27, 2012
Clinical News

ErepoXen: Phase I/IIa started

...its partner the Serum Institute began an open-label, Indian Phase I/IIa trial to evaluate IV ErepoXen...
...Xenetic Biosciences plc (LSE:XEN), London, U.K. Serum Institute of India Ltd. , Pune, India Product: ErepoXen...
BioCentury | Jan 30, 2012
Company News

Xenetic Biosciences, Serum Institute of India deal

...formerly Lipoxen plc ) said SIIL decided to focus on developing generic vaccines and Xenetic's ErepoXen...
...Xenetic will develop an undisclosed number of the returned products after focusing on development of ErepoXen...
...long-acting polysialylated form of G-CSF in preclinical testing to treat neutropenia associated with cancer chemotherapy. ErepoXen...
Items per page:
1 - 10 of 18